437_447_G

Psychiatr. Pol. 2018; 52(3): 437–447


Piotr Gałecki, Monika Talarowska

FREE POLISH FULLTEXT:

FREE ENGLISH FULLTEXT:

Summary
Brain diseases are one of the most socially and economically burdening diseases in Europe. Among all brain diseases, more than 60% of social and economic costs are generated by mental disorders (mainly depressive disorders and anxiety disorders). Recurrent depressive disorders have been a significant civilizational problem in recent times. Among the biological and psychological theories explaining the causes of depression, the hypothesis involving an active inflammatory process taking place in a human organism is becoming increasingly important. The following are considered inflammation markers: inflammatory enzymes (e.g., manganese superoxide dismutase (MnSOD), myeloperoxidase (MPO), inducible nitric oxide synthase), proinflammatory and anti-inflammatory cytokines, and the phenomenon of oxidative stress. Through the kynurenine pathway, these factors lead to a deficit in serotonin and melatonin, which is considered one of the main reasons of depression. We can consider depression to be a chronic cold of the organism, which develops in response to the action of greater or smaller everyday stressors. This paper presents results of recent studies regarding this matter.



ISSN 0033-2674 (PRINT)

ISSN 2391-5854 (ONLINE)


Psychiatria Polska
is an Open Access journal:
Creative Commons: CC-BY
SHERPA RoMEO: Blue


Zadanie finansowane
w ramach umowy
nr 739/P-DUN/2018
ze środków MNiSW
przeznaczonych
na działalność
upowszechniającą naukę



Inne strony PTP:
Other PTP websites:

www.psychiatria.org.pl
www.psychiatriapsychoterapia.pl
www.archivespp.pl
www.psychoterapiaptp.pl

Psychiatria Polska
INDEXED IN:
Thomson Reuters Master List
Science Citation Index Expanded
Journal Citation Reports
(Impact Factor 1,196)

Medline/Index Medicus
PubMed/LinkOut
MNiSW (15 pkt)
Scopus/SCImago
EMBASE/Excerpta Medica
PsycINFO, EBSCO,
Index Copernicus (153 pkt)
Erih Plus, Cochrane Library
CrossRef/DOI

We recommend:

Pharmacological Reports

 


+48  518-330-994
kontakt z Biurem KRW PTP